In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1359-1369

  Bian, Huijie ^a,c   Wilden, Holger ^a   Fournier, Philippe ^a   Peeters, Ben ^b   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biodistribution; Bispecific protein; Cancer therapy; Gene therapy; Hemadsorption; Interleukin 2 receptor; Newcastle disease virus; Real time PCR; Toxicity; Virotherapy

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; INTERLEUKIN 2 RECEPTOR; ONCOLYTIC VIRUS; VIRUS RNA;

ANIMAL; ARTICLE; DBA MOUSE; GENE TARGETING; GENE VECTOR; GENETICS; HUMAN; LEUKEMIA CELL LINE; METHODOLOGY; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; TRANSGENE; VIRULENCE; VIRUS REPLICATION;

ANIMALS; GENE TARGETING; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; JURKAT CELLS; MICE; MICE, INBRED DBA; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTORS, INTERLEUKIN-2; RNA, VIRAL; TRANSGENES; VIRULENCE; VIRUS REPLICATION;

EID: 39049178459     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1359     Document Type: Article

References (45)

1. Bell J: Replicating oncolytic virus therapeutics - Third International Meeting. Drugs 8: 360-363, 2005.
2. Horvath JC and Sinkovics JG: New biological therapeutics: competitors or collaborators of the viral therapy for human cancers. In: Viral Therapy of Human Cancers. Marcel Dekker, New York, 2004.
3. Zhang, Q, Nie M, Sham J, et al: Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 64: 5390-5397, 2004.
4. Mullen JT, Donahue JM, Chandrasekhar S, et al: Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 101: 869-877, 2004. (Pubitemid 39030946)
5. Huang S, Qu LK and Koromilas AE: Induction of p53-dependent apoptosis in HCT116 tumor cells by RNA viruses and possible implications in virus-mediated oncolysis. Cell Cycle 3: 1043-1045, 2004. (Pubitemid 40268662)
6. Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X and Curiel DT: A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 1: 321-328, 2002.
7. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781-787, 2001. (Pubitemid 32691631)
8. Matzinger P: Tolerance, danger and the extended family. Annu Rev Immunol 12: 991-1045, 1994.
9. Bristol JA, Zhu M, Ji H, et al: In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 7: 755-764, 2003.
10. Curiel DT and Douglas JT: Targeting of adenoviral gene therapy vectors: the flexibility of chemical and molecular conjugation. In: Vector Targeting for Therapeutic Gene Deliver. Wiley-Liss, USA, 2002.
11. Korn T, Nettelbeck DM, Völkel T, Müller R and Kontermann RE: Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6: 642-651, 2004.
12. Cassel WA and Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18: 863-868, 1965.
13. Sinkovics JG and Horvath JC: Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16: 1-15, 2000.
14. Nelson NJ: Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 91: 1708-1710, 1999.
15. Alexopoulou L, Holt AC, Medzhitov R and Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738, 2001. (Pubitemid 33009951)
16. Kato H, Sato S, Yoneyama M, et al: Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19-26, 2005.
17. Bian H, Fournier P, Moormann R, Peeters B and Schirrmacher V: Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 12: 295-303, 2005.
18. Bian H, Fournier P, Peeters B and Schirrmacher V: Selective gene transfer to tumor cells by recombinant Newcastle disease virus via a bispecific fusion protein. Int J Oncol 26: 431-439, 2005.
19. Bian H, Fournier P, Peeters B and Schirrmacher V: Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Int J Oncol 27: 377-384, 2005.
20. Waldmann TA: The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol 22: 51-56, 2002.
21. Zhang M Zhang Z, Garmestani K, et al: Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 100: 1891-1895, 2003.
22. Horiuchi S, Koyanagi Y, Tanaka Y, et al: Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Immunology 91: 28-34, 1997.
23. Schirrmacher V, Griesbach A and Ahlert T: Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol 18: 945-952, 2001.
24. Al-Garib SO, Gielkens AL, Gruys E, Peeters BP and Koch G: Tissue tropism in the chicken embryo of non-virulent and virulent Newcastle disease virus strains that express green fluorescence protein. Avian Pathol 32: 591-596, 2003.
25. Peeters BP, De Leeuw OS, Koch G and Gielkens AL: Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73: 5001-5009, 1999. (Pubitemid 29246761)
26. Aghi M and Martuza RL: Oncolytic viral therapies - the clinical experience. Oncogene 24: 7802-7816, 2005. (Pubitemid 41670681)
27. Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976, 2005. (Pubitemid 41766784)
28. Zeng J, Fournier P and Schirrmacher V: Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med 80: 443-451, 2002. (Pubitemid 34754210)
29. Washburn B and Schirrmacher V: Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21: 85-93, 2002.
30. Washburn B, Weigand MA, Grosse-Wilde A, et al: TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 170: 1814-1821, 2003.
31. Termeer CC, Schirrmacher V, Brocker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7: 316-323, 2000. (Pubitemid 30194568)
32. Ahlert T, Sauerbrei W, Bastert G, et al: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15: 1354-1366, 1997.
33. Karcher J, Dyckhoff G, Beckhove P, et al: Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64: 8057-8061, 2004.
34. Steiner HH, Bonsanto MM, Beckhove P, et al: Anti-tumor vaccination of patients with glioblastoma multiforme in a case-control study: feasibility, safety and clinical benefit. J Clin Oncol 22: 4272-4281, 2004.
35. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54: 587-598, 2005.
36. Nagai Y, Klenk HD and Rott R: Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 72: 494-508, 1976.
37. Pecora AL, Rizvi N, Cohen GI, et al: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266, 2002.
38. Lorence RM, Pecora AL, Major PP, et al: Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 5: 618-624, 2003.
39. Csatary LK, Gosztonyi G, Szeberenyi J, Fabioan Z, Liszka V, Bodey B and Csatary CM: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67: 83-93, 2004.
40. Gonin P and Gaillard C: Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 11: 98-108, 2004.
41. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999.
42. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor-selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338, 2006.
43. Hirasawa K, Nishikawa SG, Norman KL, et al: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353, 2003.
44. Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC and Rainov NG: Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol. J Neurooncol 64: 147-154, 2003.
45. Narendra M, Koerber JT, Kaspar BK and Schaffer DV: Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24: 198-204, 2006.